Curing Kids Cancer Through Collaboration


Improving Aggressive
Pediatric Cancer Diagnosis

The most  AGGRESSIVE & DEADLY of all solid tumors in children, adolescents, and young adults are called “Small Round Blue Cell Tumors." Not surprisingly, this describes how they appear to the pathologist under a microscope.  

Small Round Blue Cell Tumors (SRBCTs) includes four very different tumor types: 
• Neuroblastoma
• Rhabdomyosarcoma
• Non-Hodgkin Lymphoma
• Ewing's Sarcoma
SRBCTs are difficult to differentiate morphologically using existing pathology methods and criteria. No single test can precisely distinguish these tumors, so SRBCTs “diagnosis” often requires multiple expert pathologists and tests - and an excruciating length of precious time.

Unfortunately, approximately 20% of the SRBCT cases are misdiagnosed - with devastating results. Precious time is lost to ineffective treatments.

The Opportunity to Save Valuable Time and Consequently, LIVES!

Recent advancements enable these tumors to be quickly and accurately diagnosed with up to 99.9% accuracy within four hours.
Researchers at the National Cancer Institute and AltheaDx developed the SRBCT diagnostic panel at great expense using sophisticated microarray technology. This panel is able to "fingerprint" the tumor.

SRBCT Diagnostic Panel (on the right): Markers for genes that are active (red) from those that are not (green) reveal the tumor type "fingerprint."

In the current climate, companies must focus their efforts on larger markets to survive. SRBCTs are consider "rare and neglected diseases" with 1,700 new diagnoses each year in the US alone.  AltheaDx and The Nicholas Conor Institute (TNCI) have partnered to complete the panel's development and have the test available to clinics worldwide within approximately 12 months. 

Over $675,000 and multiple years are already invested in the SRBCT diagnostic panel. Furthermore, a pledge of $125,000 towards its completion is in place raising the total value of commitments to $800,000. Additionally, collaborative partnerships for panel development, panel validation, and marketing are already in place.

TNCI is seeking tax-deductible gifts and grants to complete the $250,000 needed to bring the SRBCT panel to clinic. Most importantly, a rapid and accurate solution will be available for children with the most aggressive and deadly tumors within one year!

Become a Partner to bring the SRBCT diagnostic to clinic. Contact Beth Anne Baber at (858) 227-9109 Ext.5
       "We have traditionally treated children, adolescents and young adults with cancer on cooperative-group protocols which has contributed significantly to improved outcomes during the latter part of the 20th century. However, this approach has not taken into consideration individual characteristics of the patient's tumor nor equally importantly, of the child's ability to tolerate the various chemotherapeutic agents, radiotherapy and immunotherapy prescribed.
         We are moving forward in the 21st century with an increasing ability to understand the signalling pathways involved in tumorigenesis as well as each patient's unique ability to metabolize and tolerate treatments.
         I feel strongly that a more personalized approach to diagnosis, prognosis, risk stratification and treatment planning as well as long term follow-up for late effects will ultimately result in significantly improved outcomes and decreased toxicity. The Nicholas Conor Institute is committed to this more personalized approach to the management of childhood cancer."

-Jennifer Willert, MD
Division of Hematology/Oncology/
Stem Cell Transplantion,
Stanford University Medical Center
Lucile Parkard Childrens Hospital

3525 Del Mar Heights Road, #946
•San Diego, California 92130
(858) 945-0552